相似文献
1
Assessing new health technologies: lessons to be learned from drugs.
Med J Aust. 1999 Nov 15;171(10):554-6. doi: 10.5694/j.1326-5377.1999.tb123795.x.
2
Economic evaluation approaches for new technology.
IEEE Eng Med Biol Mag. 2003 May-Jun;22(3):16-7. doi: 10.1109/memb.2003.1213621.
3
Health technology assessment in Australia: challenges ahead.
Med J Aust. 2007 Sep 3;187(5):262-4. doi: 10.5694/j.1326-5377.2007.tb01238.x.
4
HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?
Eur J Health Econ. 2020 Feb;21(1):1-5. doi: 10.1007/s10198-019-01103-9.
5
Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?
Pharmacoeconomics. 2019 May;37(5):627-630. doi: 10.1007/s40273-019-00781-w.
6
Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare.
Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):435-7. doi: 10.1080/14737167.2016.1180980. Epub 2016 May 6.
7
Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.
Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):367-9. doi: 10.1586/erp.11.50.
8
Antipodean assessment. Activities, actions, and achievements.
Int J Technol Assess Health Care. 2002 Spring;18(2):203-12. doi: 10.1017/s0266462302000223.
9
Health technology assessment in the United Kingdom.
Value Health. 2010 Jun;13 Suppl 1:S4-5. doi: 10.1111/j.1524-4733.2010.00745.x.
10
Evidence-based decision-making 3: Health technology assessment.
Methods Mol Biol. 2015;1281:417-41. doi: 10.1007/978-1-4939-2428-8_25.
引用本文的文献
1
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy.
Global Health. 2005 Oct 6;1:15. doi: 10.1186/1744-8603-1-15.
Zotero 插件